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Objective:To assess the prevalence of atherosclerotic risk factors and to investigate the added value of noninvasive imaging
in detecting asymptomatic cardiovascular diseases in patients at low risk and high risk according to the European
Guidelines on Cardiovascular Disease Prevention.
Methods: In the vascular screening program of the University Medical Center Utrecht, patients aged 18 to 79 years who
had recently received a diagnosis of manifest vascular disease (coronary heart disease, cerebrovascular disease, abdominal
aortic aneurysm, or peripheral arterial disease [PAD]) or had a risk factor (hypertension, hyperlipidemia, or diabetes
mellitus) were assessed for atherosclerotic risk factors and (other) arterial diseases by noninvasive means. The European
guidelines were applied to quantify the number of high-risk patients.
Results: Eighty-eight percent of 3950 patients were considered to be at high-risk. More than 80% had hyperlipidemia,
approximately 50% had hypertension, 21% had diabetes mellitus, and 31% were current smokers. An asymptomatic
reduced ankle-brachial index (<0.90) was most frequently observed in patients with cerebrovascular disease (21%); an
asymptomatic abdominal aortic aneurysm (>3.0 cm) in patients with PAD (5%) or cerebrovascular disease (5%); and an
asymptomatic carotid stenosis (>50%) in patients with PAD (15%). On the basis of noninvasive measurements, 73 (13%)
of 545 patients initially considered as low risk were reclassified as high risk.
Conclusions: This study confirmed a high prevalence and clustering of modifiable atherosclerotic risk factors in high-risk
patients. The yield of noninvasive vascular measurements was relatively low but identified a sizable number of high-risk
patients. Standard screening for asymptomatic atherosclerotic disease identified a limited number of vascular abnormal-
ities that necessitated immediate medical attention in patients already identified as high-risk patients. ( J Vasc Surg 2006;
43:525-32.)Cardiovascular disease (CVD) is a leading cause of
death worldwide and accounts for almost 17 million deaths
annually. Nearly 80% of these deaths occur in developed
countries, mainly as a result of the aging of the population.1
In 1994, the first European guidelines for the preven-
tion of coronary heart disease (CHD) were published,2 and
these were later revised to include lifestyle factors, athero-
sclerotic risk factors, and therapeutic goals. In 2003, the
Third Joint Task Force of European andOther Societies on
Cardiovascular Disease Prevention in Clinical Practice is-
sued the latest European guidelines on CVD in clinical
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doi:10.1016/j.jvs.2005.11.050practice in detail3 and in summary.4 Patients are catego-
rized as high- risk on the basis of well-defined conditions or
on the SCORE (Systematic COronary Risk Evaluation)
mortality risk table (Table I).5 A high absolute cardiovas-
cular risk calls for drastic lifestyle changes and medical
treatment of atherosclerotic risk factors, whereas patients at
low to moderate risk are mainly advised to adhere to a
healthy lifestyle. The European guidelines discuss the op-
portunities of noninvasive vascular measurements for iden-
tifying patients initially considered to have a low vascular
risk but, by detecting an asymptomatic atherosclerotic dis-
ease, to reconsider these patients high vascular risk. Patients
with a (recent) clinical manifestation of an atherosclerotic
disease are already classified as high-risk, but noninvasive
vascular imaging may be useful in detecting vascular abnor-
malities that necessitate immediate medical attention (eg,
aortic aneurysms and carotid artery stenosis). Because of
the generalized nature of atherosclerosis, the prevalence of
asymptomatic vascular diseases is high in these patients.6
One of the aims of the Second Manifestations of
ARTerial disease (SMART) study is to establish a protocol
for multidisciplinary care of vascular patients. The SMART
525
JOURNAL OF VASCULAR SURGERY
March 2006526 Goessens et alstudy, initiated in 1996, is an ongoing single-center pro-
spective cohort study. Patients referred to the University
Medical Center Utrecht because of clinical manifestations
of vascular disease, therapy-refractory hypertension, hy-
perlipidemia, or diabetes mellitus all underwent a stan-
dardized evaluation of atherosclerotic risk factors and non-
invasive diagnostic measurements.
In this cross-sectional study, we assessed the prevalence
of atherosclerotic risk factors and investigated the added
value of noninvasive imaging for detecting asymptomatic
CVD in patients initially considered at low-risk and in
patients already at high-risk according to the European
guidelines on Cardiovascular Disease Prevention.4
METHODS
Study setting, patients, and design. The SMART
study started in 1996. This ongoing single-center prospec-
tive cohort study has enrolled more than 5000 patients
referred to the University Medical Center Utrecht for the
treatment of clinical manifestations of atherosclerosis (in-
ternal carotid artery stenosis, transient ischemic attack or
minor stroke, peripheral arterial disease [PAD], aortic ab-
dominal aneurysm [AAA], renal artery stenosis, angina
pectoris, or myocardial infarction) or for the treatment
of major atherosclerotic risk factors, including therapy-
refractory hypertension, genetic hyperlipidemia, and type 1
or 2 diabetes mellitus. Patients were referred by general
practitioners or by medical specialists from other hospitals
in the Utrecht region. All referral diagnoses were conformed
by a vascular surgeon, internist, neurologist, nephrologist, or
cardiologist at an outpatient clinic. Patients were classified
into disease categories based on referral diagnosis and
vascular history. For definitions, see Table II. Asymptom-
atic patients were those without symptoms of clinically
manifest atherosclerosis.
Patients aged 18 to 79 years who gave their written
Table I. The European guidelines
Individuals who fulfill criteria 1, 2, or both are defined as
at high-risk
1) Patients with established CHD, PAD and cerebrovascular
disease
2) Asymptomatic individuals who are at high-risk of developing
CVD because of:
a) Multiple risk factors resulting in a 10 year risk of  5%
(SCORE) for developing a fatal cardiovascular event
b) Markedly raised levels of single risk factors: cholesterol 
8.0 mmol/L LDL-cholesterol  6.0 mmol/L, blood
pressure  180/110 mmHg
c) Diabetes type 2 and diabetes type 1 with
microalbuminuria
3) Close relatives (first degree relatives) of:
a) Patients with early-onset of CVD
b) Asymptomatic individuals at particularly high-risk
4) Other individuals met in connection with ordinary clinical
practice
Source: De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova
R, Dallongeville J et al. Eur Heart J 2003;24:1601-1610.informed consent were included. Patients with a life expect-ancy shorter than 2 years, those with terminal malignant
disease, those dependent in daily activities (Rankin grade
3), and those not proficient in Dutch were excluded. The
ethics committee of our institution approved the study.
The rationale and design of the SMART study have been
described in detail elsewhere.7 For the current cross-sectional
study, the datawere usedof the first consecutive 3950patients
included from September 1996 to March 2004.
Vascular screening. All included patients underwent
a standardized noninvasive screening (ankle-brachial pres-
sure index [ABPI], duplex scan of the carotid arteries,
ultrasonography of the abdomen, electrocardiogram
[ECG]) and laboratory assessment (blood and urine anal-
yses). Patients completed questionnaires on the history
of CVD (CHD, PAD, and cerebrovascular disease), risk
factors (diabetes mellitus, hypertension, hyperlipidemia,
smoking, alcohol consumption, physical activity, and famil-
ial vascular history), and current medication use. The self-
reported data were compared with information from the
physician’s letter, and missing information was added by
research nurses. Height, weight, waist circumference, and
blood pressure were measured according to a standardized
diagnostic protocol. Fasting blood was sampled to deter-
mine serum glucose, total cholesterol, high-density li-
poprotein HDL cholesterol, triglycerides, creatinine, and
homocysteine levels. Glucose, total cholesterol, triglycer-
ides, and creatinine were measured with a commercial
enzymatic dry chemistry kit (New Brunswick: Johnson &
Johnson), HDL cholesterol was measured with a commer-
cial enzymatic kit (Mannheim: Boehringer), and homocys-
teine was analyzed with the Shipchandler and Moore
method.8 The low-density lipoprotein (LDL) cholesterol
level was calculated with Friedewald’s formula. An early
morning urine portion was collected to measure the albu-
min and creatinine concentrations. A 12-lead resting ECG
was recorded, and ultrasonography was performed to assess
the presence of asymptomatic atherosclerosis. Ultrasound
examinations were performed by well-trained registered
vascular technologists in a certified vascular laboratory.
Ultrasonography of the abdomen was performed with an
ATL 3000 HDI (Advanced Technology Laboratories)
equipped with a 4-MHz curved-array transducer to mea-
sure the anteroposterior juxtarenal diameter and the distal
anteroposterior diameter of the aorta. The presence of
plaques and stenosis of the common and internal carotid
arteries on both sides was assessed with color Doppler-
assisted duplex scanning. The left and right ABPIs at rest
were determined by taking the ratios of the highest
systolic blood pressure measured at the ankle to the
highest systolic blood pressure in both arms with the pa-
tient in the supine position.
All patients visited the hospital after an overnight fast of
at least 8 hours and underwent the total vascular screening
program within 2 hours. The direct costs of the vascular
screening were approximately €900.00 (US$1098.00) per
patient in 2004.
Multidisciplinary treatment recommendations. The
results of the vascular screening program were discussed at
hial pr
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of an internist, vascular surgeon, cardiologist, nurse practi-
tioner, and, on request, neurologist. The target goals for
patients with established CVD were quitting smoking and
achieving a body mass index less than 25 kg/m2, blood
pressure less than 140/90 mm Hg, total cholesterol less
than 5.0 mmol/L, LDL cholesterol less than 3.0 mmol/L,
and plasma glucose level less than 7.0 mmol/L. If these
targets were exceeded, treatment was given according to the
Third Joint Task Force of European Societies recommenda-
tions4 and the best available evidence for the treatment of
atherosclerotic risk factors—namely, hypertension,9,10 diabe-
tes mellitus/insulin resistance, hyperlipidemia, hyperhomo-
cysteinemia,11,12 obesity,13 smoking,14,15 and microprotein-
uria16,17—as well as asymptomatic arterial disease (AAA,18
carotid stenosis,19-21 and low ABPI22). The results of the
vascular screening and the treatment recommendations
were reported in writing to the treating specialist and the
general practitioner, and further action was left to their
discretion. Patients were not informed by mail.
European guidelines on CVD prevention. The ob-
jective of the European guidelines on CVD prevention in
clinical practice is to reduce the incidence of the first event
or recurrent clinical events.4 Preventive efforts are most
efficient in those at highest risk. Patients with established
atherosclerotic disease, asymptomatic individuals with a
10-year mortality risk of 5% or more with the SCORE
chart, those with markedly increased levels of single risk
factors, and those with type 2 diabetes or type 1 diabetes
with microalbuminuria are considered at high risk, as are
Table II. Classification of disease categories based on refe
Disease category Inc
Cerebrovascular disease Cerebral ischemia, transient isch
ischemic stroke, retinal infarc
stenosis with diameter reduct
Coronary heart disease Myocardial infarction—at least
1. Chest pain for at least 20 min
of nitrates
2. ST elevation 1 mm in 2 fol
block on the ECG
3. CK elevation of at least 2 tim
fraction 5% of the total CK
Angina pectoris: chest pain with
ECG and with documented s
Peripheral arterial disease Intermittent claudication, rest p
Aneurysm of abdominal aorta Distal aortic anteroposterior dia
ratio 1.5 cm
Hypertension Systolic BP 140 mm Hg, dias
agent use
Hyperlipidemia Total cholesterol 5.0 mmol/L
or lipid-lowering drug use
Diabetes mellitus type 1 and 2 Fasting glucose 7.0 mmol/L,
or oral antidiabetic drug or in
ECG, Electrocardiogram; CK, creatinine kinase; MB, myocardial band; C
angioplasty; PTA, percutaneous transluminal angioplasty; ABPI, ankle brac
*Ever or current diagnosis.asymptomatic patients with preclinical evidence of athero-sclerosis. There are two SCORE charts: one for low-risk
regions and one for high-risk regions.5 The Netherlands is
classified as a high-risk region in Europe. Although there
are no studies to date comparing the Framingham risk
equation with the SCORE algorithm, the 10-year mortality
risk of 5% by SCORE is considered to be roughly equal to
the 10-year vascular event risk (including vascular mortal-
ity) of 20% by the Framingham risk equation.
Data analysis. Continuous variables are presented as
means with standard deviations. The prevalence of athero-
sclerotic risk factors and asymptomatic arterial disease is
expressed as a percentage with corresponding 95% confi-
dence interval. The 10-year risk estimate for fatal CVD was
calculated for the potentially low-risk patients with the
high-risk SCORE chart.
RESULTS
From September 1, 1996, to March 31, 2004, 3950
patients were enrolled in the SMART study with the fol-
lowing confirmed referral diagnoses: PAD (15%), cerebro-
vascular disease (17%), CHD (26%), AAA (6%), diabetes
mellitus (10%), hyperlipidemia (13%), or hypertension (13%).
Table III describes the baseline characteristics and medica-
tion use of the population. Sixty-nine percent of the pa-
tients were male; the mean age was 57  12 years for men
and 54  14 years for women. The prevalence of “ever
smokers” was highest among patients who presented with
AAA (90%). A history of CHD was most common among
patients who were referred with AAA (38%). A previous
diagnosis of AAA was relatively uncommon. Drug treat-
iagnosis and vascular history
diagnosis Vascular history*
attack, amaurosis fugax, minor
or asymptomatic carotid artery
30%
Transient ischemic
attack; stroke
he following criteria: Myocardial infarction;
angina pectorisdisappearing after administration
g leads or a left bundle branch CABG or PTCA
e normal value of CK and an MB
ithout documented ischemia on the
is on the angiography
angrene, ulcers, resting ABPI 0.90 Arterial operation; PTA
leg; amputation leg
r 3.0 cm and/or distal/proximal Surgery for aneurysm
BP 90 mm Hg, or antihypertensive
L cholesterol 3.0 mmol/L,
asting glucose 11.0 mmol/L,
use
coronary artery bypass graft; PTCA, percutaneous transluminal coronary
essure index; BP, blood pressure; LDL, low-density lipoprotein.rral d
lusion
emic
tion,
ion 
2 of t
not
lowin
es th
or w
tenos
ain, g
mete
tolic
, LD
nonf
sulin
ABG,ment of risk factors was most common in patients with
d oth
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of clinically manifest disease.
Table IV shows the prevalence of atherosclerotic risk
factors according to the presenting disease. A total of
3448 (87%) of the 3950 patients had hypercholesterol-
emia (total cholesterol 4.5 mmol/L or LDL choles-
terol 2.5 mmol/L), of which 34% were taking lipid-
lowering medication at baseline. A total of 2131 patients
were hypertensive (140/90 mm Hg), and 58% were
taking antihypertensivemedication. Diabetes mellitus (fast-
ing glucose 7.0 mmol/L) was detected in 841 (21%) of
the 3950 patients, and exactly half of these patients were
Table III. Baseline characteristics of the study population
Variable
PAD
(n  604)
Cerebro
(n  650)
CHD
(n  1034)
Male sex 397 (66) 485 (75) 854 (83)
Age (male), y (SD) 59 (10) 62 (10) 58 (9)
Age (female), y (SD) 59 (12) 60 (11) 61(10)
Systolic BP, mm Hg (SD) 146 (22) 148 (22) 135 (19)
Diastolic BP, mm Hg (SD) 80 (10) 82 (11) 78 (10)
BMI, kg/m2 (SD) 26 (4) 26 (4) 27 (4)
Ever smoker 525 (87) 527 (81) 769 (74)
History of vascular events*
PAD 43 (7) 37 (4)
Cerebrovascular 48 (8) 21 (2)
CHD 127 (21) 104 (16)
AAA 26 (4) 25 (4) 15 (2)
Antihypertensive drugs 241 (40) 308 (47) 844 (82)
Lipid-lowering agents 149 (25) 235 (36) 586 (57)
Glucose-lowering agents 67 (11) 74 (11) 88 (9)
Antiplatelet agents 272 (45) 504 (78) 761 (74)
PAD, Peripheral arterial disease; CHD, coronary heart disease; AAA, abdo
Data represent the number of patients (%) or mean (SD); cerebro: cerebrov
*Documented as PAD, cerebrovascular disease, CHD, or AAA in history an
Table IV. Risk factors of the study population (n  3950
Variable
PAD
(n  604)
Cerebro
(n  650)
CHD
(n  10
Total cholesterol 4.5 mmol/L 527 (87) 533 (82) 735 (7
LDL cholesterol 2.5 mmol/L 528 (87) 532 (82) 735 (7
Systolic BP 140 mm Hg and/
or diastolic BP 90 mm Hg 339 (58) 408 (65) 382 (3
Impaired glucose tolerance
6.1 to 6.9 mmol/L 119 (20) 121 (19) 189 (1
Plasma glucose 7.0 mmol/L 125 (21) 107 (17) 157 (1
Homocysteine 15.0 mol/L 146 (24) 181 (28) 261 (2
Creatinine clearance
60 mL/min per 1.73 m2 128 (21) 156 (24) 123 (1
60-90 mL/min per 1.73 m2 298 (49) 352 (54) 587 (5
Microalbumin 30.0 mg/mmol 102 (17) 97 (15) 71 (7
PAD, Peripheral arterial disease; CHD, coronary heart disease; AAA, abd
BP, blood pressure; cerebro: cerebrovascular disease.
Data represent the number of patients (%) or mean (SD).
*Blood pressure 130/80 mm Hg in patients with DM.taking glucose-lowering medication at baseline. An in-creased level of homocysteine (15.0 mol/L) was most
prevalent in patients with AAA (43%). Approximately 93%
of the patients had at least one risk factor for CVD (hyper-
tension, hyperlipidemia, diabetes, increased homocysteine
level, or current smoking), and 73% had two or more risk
factors (data not shown).
The prevalence of a reduced ABPI (0.90) was highest
in patients with cerebrovascular disease (21%), a carotid
stenosis of 50% or more was most frequently found in
patients with PAD (15%), and a dilated abdominal aorta of
3.0 cm or more was found in 5% of the patients with PAD
or cerebrovascular disease (Table V). An AAA of 5.5 cm or
3950)
rral diagnosis
Total
(n  3950)
AA
239)
DM
(n  403)
Hyperlipidemia
(n  528)
Hypertension
(n  492)
6 (95) 231 (57) 316 (60) 229 (47) 2738 (69)
8 (7) 49 (15) 45 (11) 52 (12) 57 (12)
9 (8) 49 (14) 47 (14) 49 (14) 54 (14)
5 (19) 136 (19) 135 (17) 154 (22) 142 (21)
5 (11) 81 (11) 81 (11) 95 (13) 82 (12)
6 (3) 28 (6) 26 (4) 27 (5) 27 (4)
5 (90) 154 (39) 175 (34) 191 (40) 2556 (65)
2 (5) 10 (3) 8 (2) 8 (2) 118 (4)
8 (8) 14 (4) 18 (3) 32 (7) 151 (5)
1 (38) 41 (10) 47 (9) 29 (6) 439 (15)
9 (2) 6 (1) 18 (4) 99 (3)
2 (51) 154 (38) 120 (23) 335 (68) 2124 (54)
5 (27) 79 (20) 234 (44) 79 (16) 1427 (36)
7 (3) 292 (73) 28 (5) 32 (7) 588 (15)
1 (42) 59 (15) 78 (15) 70 (14) 1845 (47)
aortic aneurysm; DM, diabetes mellitus; BMI, body mass index.
r disease.
er than the referral diagnosis.
eferral diagnosis
Total
(n  3950)
AAA
n  239)
DM
(n  403)
Hyperlipidemia
(n  528)
Hypertension
(n  492)
201 (84) 291 (72) 478 (91) 421 (86) 3185 (81)
206 (86) 293 (73) 474 (90) 414 (84) 3182 (81)
139 (60) 273 (69)* 207 (40) 383 (80) 2131 (54)
49 (21) 29 (7) 55 (10) 75 (15) 637 (16)
31 (13) 322 (80) 52 (10) 47 (10) 841 (21)
103 (43) 67 (17) 80 (15) 136 (28) 974 (25)
102 (43) 39 (10) 14 (3) 69 (14) 631 (16)
116 (49) 121 (30) 215 (41) 211 (43) 1900 (48)
48 (20) 67 (17) 35 (7) 73 (15) 493 (13)
al aortic aneurysm; LDL, low-density lipoprotein; DM, diabetes mellitus;(n 
Refe
A
(n 
22
6
6
14
8
2
21
1
1
9
12
6
10
minal
ascula)
R
34) (
1)
1)
8)
8)
5)
5)
2)
7)
)
ominmore was rare (in only five patients with CVD). In patients
sterior
minal
.
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factors, a reduced ABPI was most prevalent in patients with
diabetes (5%); carotid stenosis of 50% or more, in patients
with hypertension (4%); and an AAA of 3 cm or more, in
patients with hypertension (2%).
In the Figure, the distribution of high-risk versus low-
risk patients is shown. Patients with established CVD (n 
2527), individuals referred with a risk factor and a vascular
history (n  151), or patients with type 2 diabetes (n 
275) or type 1 diabetes with microalbuminuria (n  22)
are immediately considered at high risk. The low-risk pa-
tients with markedly increased levels of single risk factors
(total cholesterol 8.0 mmol/L, LDL cholesterol 6.0
mmol/L [n 165], or blood pressure180/110 mmHg
[n  106]) or a 10-year mortality risk of 5% or more
calculated with the high-risk SCORE chart (n 159) were
also considered to be at high risk. Patients referred with an
atherosclerotic risk factor and with asymptomatic athero-
sclerosis (reduced ABPI [n  5], carotid stenosis of 50%
[n  10], an AAA of 3 cm [n  1], or a mean carotid
intima-media thickness [CIMT] 1.0 mm [n  19]) or
signs of left ventricular hypertrophy (n  38) were also
considered high-risk patients. Hence, we identified 3478
Table V. Prevalence (%) of new ultrasonographic and ank
Variable
PAD
(n  604)
Cerebro
(n  650)
CHD
(n  1034
Ankle brachial index 0.90* 137 64
%: 95% CI 21: 18-24 6: 5-8
A. carotid stenosis 50%† 93 63
%: 95% CI 15: 13-18 6: 5-8
A. carotis stenosis 70%† 67 32
%: 95% CI 11: 9-14 3: 2-4
AAA distal aorta 3.0 cm‡ 27 32 23
%: 95% CI 5: 3-6 5: 3-7 2: 1-3
AAA distal aorta 5.5 cm‡ 1 3 1
%: 95% CI 0 1 0
PAD, Peripheral arterial disease; CHD, coronary heart disease; AAA, abdo
Data represent number of patients with percentages and 95% confidence in
*Measurement of the systolic blood pressure in the left and right brachial a
†Duplex ultrasonography of both carotid internae arteries and based on a p
‡Ultrasonography of the anteroposterior juxtarenal and the distal anteropo
Table VI. Medication use at baseline according to referra
Variable
PAD
(n  604)
Cerebro
(n  650)
CHD
(n  1034
Antiplatelet agents 221 (37) 469 (72) 712 (69)
Vitamin K–antagonist agents 58 (10) 49 (8) 78 (8)
Lipid-lowering agents 149 (25) 235 (36) 586 (57)
Glucose-lowering agents 67 (11) 74 (11) 88 (9)
Antihypertensive drugs 241 (40) 308 (47) 844 (82)
Folic acid use 15 (3) 33 (5) 21 (2)
PAD, Peripheral arterial disease; CHD, coronary heart disease; AAA, abdo
Data represent the number of patients (%); cerebro: cerebrovascular disease(88%) high-risk patients who required the most intensivelifestyle intervention and drug therapy according to inter-
national guidelines.
The number of high-risk patients receiving medication
at baseline is given in Table VI. The most infrequent use of
antiplatelet agents was in patients with AAA (32%), and the
most frequent use was in patients with cerebrovascular
disease (72%). Antihypertensive drugs were the most used
category of medication. Patients with CHD used more
lipid-lowering agents (57%) than did patients with PAD
(25%). Less than 6% of patients with established CVD or a
risk factor for atherosclerosis took folic acid.
DISCUSSION
This study confirmed a high prevalence and clustering
of modifiable atherosclerotic risk factors in high-risk pa-
tients. The yield of noninvasive vascular measurements was
relatively low but identified a sizable number of patients
who were initially considered as low risk but who, by
detection of asymptomatic atherosclerotic vascular disease,
could be considered as high-risk patients. Standard screen-
ing for asymptomatic atherosclerotic disease identified a
limited number of vascular abnormalities that necessitated
immediate medical attention in patients already identified
achial index findings (n  3950)
erral diagnosis
Total
(n  3950)
AAA
 239)
DM
(n  403)
Hyperlipidemia
(n  528)
Hypertension
(n  492)
47 19 13 15 295
: 15-25 5: 3-7 3: 1-4 3: 2-5 8: 7-8
28 11 13 19 227
: 8-16 3: 1-5 3: 1-4 4: 2-6 6: 5-7
20 5 8 12 144
: 5-13 1: 0-3 2: 1-3 2: 1-4 4: 3-4
5 2 12 101
1: 0-3 0: 0-1 2: 1-4 3: 2-3
— — — 2 7
0 0
aortic aneurysm; DM, diabetes mellitus.
(CIs); cerebro: cerebrovascular disease.
and both posterior tibial and dorsalis pedis arteries.
stolic velocity 150 cm/s.
diameter of the aorta.
nosis (n  3478)
AAA
 239)
DM
(n  320)
Hyperlipidemia
(n  321)
Hypertension
(n  310)
Total
(n  3478)
7 (32) 44 (14) 57 (18) 54 (17) 1634 (47)
6 (11) 16 (5) 8 (3) 5 (2) 240 (7)
5 (27) 75 (23) 148 (46) 60 (19) 1318 (38)
7 (3) 236 (74) 19 (6) 27 (9) 518 (15)
2 (51) 145 (54) 89 (28) 218 (70) 1967 (57)
— 9 (3) 9 (3) 16 (5) 103 (3)
aorta aneurysm; DM, diabetes mellitus.le-br
Ref
) (n
20
12
8
minal
tervals
rteries
eak syl diag
) (n
7
2
6
12as high-risk patients. The high prevalence and clustering of
JOURNAL OF VASCULAR SURGERY
March 2006530 Goessens et almajor atherosclerotic risk factors in our study were in
agreement with previously reported findings of high preva-
lences of atherosclerotic risk factors among patients with
PAD,23,24 CHD,25-27 cerebrovascular disease,28 and AAA.29
New imaging methods, such as magnetic resonance
imaging and computed tomography to detect coronary
calcifications or ultrasonography to measure CIMT, can be
used to detect asymptomatic individuals at high risk of
cardiovascular events. The European guidelines refer to
these methods as an extra option to identify patients at high
risk for new cardiovascular events. In our cohort, we were
able to use a set of vascular diagnostic modalities that were
all noninvasive, validated, safe, and relatively inexpensive.
All included patients underwent the complete vascular
screening protocol, and no selection was made in patients
who could benefit more or less from the screening. The
yield of screening for a reduced ABPI, carotid artery steno-
sis, AAA, increased mean CIMT, or left ventricular hyper-
trophy was low in patients referred for poorly controlled
risk factors (diabetes mellitus, hyperlipidemia, or hyperten-
sion). On the basis of noninvasive measurements, 73 pa-
tients (13%) could be reclassified from the initially low-risk
group to the high-risk category (Fig). The measurement
with the highest yield of newly detected high-risk patients
was an ECG fulfilling the criteria of left ventricular hyper-
trophy (38 of 545 patients). In patients with hypertension,
Fig 1. Categorization of SecondManifestations of ARTerial disease
(SMART) patients into high and low risk. CVD, cardiovascular dis-
ease; DM, diabetes mellitus; microalb, microalbuminuria; LDL, low-
density lipoprotein; SCORE, Systematic COronary Risk Evaluation;
IMT, intima-media thickness; ECG, electrocardiogram.hyperlipidemia, or diabetes, the overall prevalence of ca-rotid artery stenosis (50%) was 3%. Jones et al30 detected
2 carotid stenoses in 92 patients with diabetes, and Sutton
et al31 found a prevalence of 25% in 187 hypertensive
participants. We detected only 1 AAA (3 cm) in 545
low-risk patients. Others found 24 (3%) AAAs among 918
patients with hypertension.32 We found a reduced ABPI in
five low-risk patients. The prevalence of PAD was much
higher (approximately 20%) among 6880 primary care
patients in Germany.33 The discrepancies between our
ultrasound findings and other results can be partly ex-
plained by differences in diagnostic criteria or from differ-
ences in study populations and ultrasound methods. We
found a mean CIMT of greater than 1 mm in 19 of 545
low-risk patients. An increased CIMT is associated with
both CVD risk factors and atherosclerosis elsewhere in the
arterial system.34 CIMT could be a suitable indicator of
atherosclerotic burden in asymptomatic patients, but fur-
ther research is needed to confirm this.
The clinical and prognostic relevance of asymptomatic
atherosclerosis detected with additional screening in low-
risk patients is not known. To our knowledge, no other
comparable studies have published results of additional
noninvasive vascular screening in low-risk patients, and the
cost-effectiveness remains to be determined. Carotid end-
arterectomy is well established as a beneficial procedure for
reducing the risk of stroke among patients with symptom-
atic high-grade carotid artery disease.35 Screening for
asymptomatic carotid artery stenosis may be relevant now
that some trials have shown that carotid endarterectomy in
asymptomatic patients resulted in small reductions in the
incidence of transient cerebral ischemia,21 nondisabling
stroke,19 and fatal or disabling stroke.20 In patients with an
asymptomatic AAA smaller than 5.5 cm, ultrasonographic
surveillance is to be preferred to surgical or endovascular
treatment.18 Asymptomatic PAD, as indicated by a reduced
ABPI, points to diffuse atherothrombotic disease and to
the need for treatment. Successful treatment strategies
include atherosclerotic risk factor modification, particularly
smoking cessation; initiation of regular exercise; control of
hypertension, diabetes, and hyperlipidemia; and use of
antiplatelet agents to reduce the risk of atherothrombotic
events.18
The prevalence of severe asymptomatic vascular abnor-
malities was more common in patients already known to be
at high risk compared with the lower-risk patients. An
asymptomatic reduced ABPI was found most often in
patients who were included with cerebrovascular disease
(21%) or AAA (20%). A carotid stenosis of 50% was
mostly found in patients with PAD (15%) as well as a
carotid stenosis of 70% or more (11%), and a dilated ab-
dominal aorta of 3.0 cm or more was found in only 5% of
the patients with PAD and in 5% of the patients with
cerebrovascular disease. The additional screening to detect
concomitant asymptomatic atherosclerosis (carotid steno-
sis50% and70%; AAA3.0 cm and5.5 cm) is not of
clinical relevance in patients already known to be at high
risk. These patients already require the most intensive life-
style intervention and, where appropriate, drug treatment
JOURNAL OF VASCULAR SURGERY
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be justified only if it could identify severe asymptomatic
vascular disorders, such as AAA 5.5 cm or more. In 3478
already-high-risk patients, we identified only 7 (0.2%) pa-
tients with an AAA of 5.5 cm or more (Table V).
The prevalence of asymptomatic vascular abnormalities
necessitating immediate medical attention was low in high-
risk patients. Besides the fact that in our study the preva-
lence of asymptomatic vascular abnormalities was also low
in low-risk patients, the prognostic relevance of asymptom-
atic vascular abnormalities in low-risk patients is not
known. It is therefore questionable whether the detection
of such vascular abnormalities justifies shifting these ini-
tially low-risk patients to the high-risk category. A cost-
effectiveness analysis was not performed, but the yield of
screening seems not worth the effort. Still, this needs to be
further studied. For the moment, it would seem more
appropriate to focus on the management of major athero-
sclerotic risk factors (hypertension, hyperlipidemia, and
diabetes) and the use of antithrombotic therapy and to
repeatedly address the role of lifestyle changes (quit smok-
ing, adopt a healthy diet, and increase physical activity).
In conclusion, the prevalence of modifiable risk factors
in high-risk patients is high. Although the yield of nonin-
vasive vascular measurements was relatively low in patients
referred for a poorly controlled risk factor, it led to addi-
tional identification of high-risk patients. Standard screen-
ing for asymptomatic atherosclerotic disease identified a
limited number of vascular abnormalities that necessitated
immediate medical attention and intervention in patients
already identified as high-risk patients. The results of this
study indicate that standard noninvasive vascular screening
in patients already at high risk for the development of
vascular diseases has little added benefit and cannot be
recommended in general practice.
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APPENDIX
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Algra, MD, PhD, Y. van der Graaf, MD, PhD, D. E.
Grobbee, MD, PhD, and G. E. H. M. Rutten, MD, PhD,
Julius Center for Health Sciences and Primary Care; J. D.
Banga,MD, PhD, and F. L. J. Visseren,MD, PhD, Depart-
ment of Vascular Medicine; H. A. Koomans, MD, PhD,
Department of Nephrology; B. C. Eikelboom, MD, PhD,
and F. L. Moll, MD, PhD, Department of Vascular Surgery;
L. J. Kappelle, MD, PhD, Department of Neurology;
W. P. T. M. Mali, MD, PhD, Department of Radiology; and
P.A. Doevendans, MD, PhD, Department of Cardiology.
